close

Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications. The company uses phage display, a drug discovery technology to identify antibody, small protein, and peptide compounds for clinical development. It offers DX-88, an ecallantide, which is in late stage clinical trial development in two indications. The advanced indication for DX-88 involves the treatment of hereditary angioedema, a life-threatening inflammatory condition, which completed three Phase II trials and two Phase III trials; and the second indication for DX-88 is for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which completed a Phase I/II trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. The company also has other biopharmaceutical discovery and development programs, primarily DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. It also provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. The company has co-development collaboration agreements with Athera, CSIRO, and Syntonix Pharmaceuticals; and licensing agreements with Cubist Pharmaceuticals, sanofi-aventis, and Fovea Pharmaceuticals. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.52
Volume	97546
Volume Avg	294800
52 Week High	2.33
52 Week Low	1.10
PE	N/A
PE (group average)	39
EPS Year	-0.35
EPS change Q/Q	-22.22%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	-22.22%
EPS change Y/Y	-47.22%
REV change Q/Q	-11.83%
REV change Q/Q Yr ago	-59%
EPS next Q est	-0.09
EPS next Y est	-0.11
Divident Annual	0.00
Dividend Yield	0%